Literature DB >> 17443492

SFRP1 suppressed hepatoma cells growth through Wnt canonical signaling pathway.

Yu-Lueng Shih1, Chung-Bao Hsieh, Hung-Cheng Lai, Ming-De Yan, Tsai-Yuan Hsieh, You-Chen Chao, Ya-Wen Lin.   

Abstract

Oncogenic activation of the Wnt/beta-catenin signaling pathway is common in hepatocellular carcinoma (HCC). The secreted frizzled-related proteins (SFRPs) function as negative regulators of Wnt signaling and have important implications for carcinogenesis. Promoter hypermethylation of SFRP genes is common in human cancers. However, the role of SFRPs in HCC is not clear. Recently, we have shown that SFRP1 is frequently downregulated through promoter hypermethylation. To confirm and extend these findings, the methylation status of the other SFRP members, including SFRP2, SFRP4 and SFRP5, was examined by methylation-specific polymerase chain reaction (MS-PCR). Hypermethylation of SFRP genes, except for SFRP4, is frequent in HCCs and the levels found here were significantly higher than those seen in cirrhotic livers, chronic hepatitis livers and normal controls (p < 0.0001 for SFRP1 and SFRP2, p < 0.05 for SFRP5). To investigate the role of SFRP1 in HCCs, we used re-expression of SFRP1 in beta-catenin-dependent HCC cell lines: Huh6 and HepG2. Restoration of SFRP1 attenuated Wnt signaling in those Huh6 hepatoma cells with a beta-catenin gene point mutation, decreased abnormal accumulation of beta-catenin in the nucleus and suppressed cell growth. Conversely, restoration of SFRP1 in HepG2 hepatoma cells with truncated beta-catenin could not block the Wnt signaling pathway. Furthermore, knocking down SFRP1 by RNA interference in beta-catenin-deficient cell lines (SK-Hep1) stimulated Wnt signaling and promoted cell growth. Our data suggested that SFRP1 suppressed liver cancer cells growth through Wnt canonical signaling. Moreover, beta-catenin-independent noncanonical pathway might be involved in Wnt signaling activation through unknown molecules in HCC. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17443492     DOI: 10.1002/ijc.22750

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  33 in total

Review 1.  Identification of driver and passenger DNA methylation in cancer by epigenomic analysis.

Authors:  Satish Kalari; Gerd P Pfeifer
Journal:  Adv Genet       Date:  2010       Impact factor: 1.944

2.  Methylation-associated silencing of SFRP1 with an 8p11-12 amplification inhibits canonical and non-canonical WNT pathways in breast cancers.

Authors:  Zeng-Quan Yang; Gang Liu; Aliccia Bollig-Fischer; Ramsi Haddad; Adi L Tarca; Stephen P Ethier
Journal:  Int J Cancer       Date:  2009-10-01       Impact factor: 7.396

Review 3.  Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies.

Authors:  Saad Saffo; Tamar H Taddei
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

4.  Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers.

Authors:  Simon J Cooper; Christina A von Roemeling; Kylie H Kang; Laura A Marlow; Stefan K Grebe; Michael E Menefee; Han W Tun; Gerardo Colon-Otero; Edith A Perez; John A Copland
Journal:  Mol Cancer Ther       Date:  2012-07-23       Impact factor: 6.261

5.  Prognostic value of Wnt inhibitory factor-1 expression in hepatocellular carcinoma that is independent of gene methylation.

Authors:  Liang Huang; Mei-Xiang Li; Li Wang; Bin-Kui Li; Gui-Hua Chen; Li-Ru He; Li Xu; Yun-Fei Yuan
Journal:  Tumour Biol       Date:  2010-10-30

6.  Proliferation and pluripotency of human embryonic stem cells maintained on type I collagen.

Authors:  Meredith B Jones; Chia H Chu; James C Pendleton; Michael J Betenbaugh; Joseph Shiloach; Bolormaa Baljinnyam; Jeffrey S Rubin; Michael J Shamblott
Journal:  Stem Cells Dev       Date:  2010-10-12       Impact factor: 3.272

7.  The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines.

Authors:  Brigette B Y Ma; Fion Sung; Qian Tao; Fan Fong Poon; Vivian W Lui; Winnie Yeo; Stephen L Chan; Anthony T C Chan
Journal:  Invest New Drugs       Date:  2009-01-27       Impact factor: 3.850

Review 8.  Wnt signaling in liver cancer.

Authors:  Yutaka Takigawa; Anthony M C Brown
Journal:  Curr Drug Targets       Date:  2008-11       Impact factor: 3.465

9.  Methylation analysis of SFRP genes family in cervical adenocarcinoma.

Authors:  Ya-Wen Lin; Ming-Tzeung Chung; Hung-Cheng Lai; Ming De Yan; Yu-Leung Shih; Cheng-Chang Chang; Mu-Hsien Yu
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-10       Impact factor: 4.553

10.  Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells.

Authors:  Wei Wei; Mei-Sze Chua; Susan Grepper; Samuel K So
Journal:  Mol Cancer       Date:  2009-09-24       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.